1. Home
  2. GRI vs AEMD Comparison

GRI vs AEMD Comparison

Compare GRI & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.31

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

HOLD

Current Price

$2.17

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRI
AEMD
Founded
2018
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.6M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
GRI
AEMD
Price
$2.31
$2.17
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$160.00
$15.00
AVG Volume (30 Days)
73.1K
10.4K
Earning Date
05-14-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.31
52 Week High
$6.70
$5.89

Technical Indicators

Market Signals
Indicator
GRI
AEMD
Relative Strength Index (RSI) 46.40 48.07
Support Level $2.15 $2.00
Resistance Level $2.72 $2.46
Average True Range (ATR) 0.19 0.12
MACD -0.01 -0.02
Stochastic Oscillator 37.12 23.08

Price Performance

Historical Comparison
GRI
AEMD

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.

Share on Social Networks: